Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer.
暂无分享,去创建一个
S. Heimfeld | M. Andreeff | R. Giles | A. Deisseroth | F. Holmes | E. Mechetner | J. Kavanagh | J. Ostrove | D. Claxton | E. Hanania | R. Champlin | D. Ellerson | C. Verschraegen | L. Calvert | T. Holzmayer | Z. Rahman | R. Berenson | R. Mehra | C. Bachier | J. Hamer | Z. Zu | J. Gajewski | S. Fu | A. Kudelka | A. Dayne
[1] J. Pater,et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Armitage,et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Hegewisch-Becker,et al. Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. , 1995, Gene therapy.
[4] M. Gottesman,et al. Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. , 1995, Gene therapy.
[5] G. Bonadonna,et al. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.
[6] S. Heimfeld,et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. , 1994, Blood.
[7] G. Hortobagyi,et al. Factors predicting long‐term survival for metastatic breast cancer patients treated with high‐dose chemotherapy and bone marrow support , 1994, Cancer.
[8] A. Deisseroth,et al. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. , 1994, Cancer gene therapy.
[9] I. Pastan,et al. Transfer and expression of the human multiple drug resistance gene into live mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[10] I. Pastan,et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. , 1992, Science.
[11] I. Tannock,et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Levine,et al. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] W. Hryniuk,et al. The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] B. Teicher,et al. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. , 1988, Cancer research.